Planet Earth, we’re Petal. And we are making healing human.
We live in a world where unfortunately, at least 2 billion people across the globe lack access to safe surgical care . And even those of us who do have access to care, about 4 million die as a result of surgery or complications stemming from invasive procedures each year.
Modern surgery still requires incisions, creating more harm before the healing can begin, not to mention the lack of access related to all the complexity that comes with the entire surgical setup. The status quo for surgery as we know it today still means that patients experience pain, trauma, complications, and sometimes, even death, regardless of access.
But what if Surgery did not require cuts? How would access, and patient experience change?
We imagine that world. And because of recent advances on multiple technology fronts, we are realizing a better way to enable surgery – a way to make healing human.
At Petal, we see a world where healing doesn’t begin with harm. We’re developing a new approach to surgery using acoustic liquefaction (a unique form of histotripsy), AI, and robotics. We call it incisionless surgery — a new standard of care that eliminates cutting, pain, trauma, and much of the typical risks inherent to traditional surgery from most procedures. No cuts, no burns, no toxicity. Then the body heals itself naturally.
On our way to take our solution to the patients, we’ve raised nearly $20M in total funding, including a $10M Series A that was co-led by K 50 Ventures and TSVC, with participation from Draper’s, ShangBay Capital, Eliot Horowitz, Dr. Frederic H. Moll and other notable VCs and industry pioneers.
“Lack of surgery access is a major obstacle to proper healthcare, and Petal has built something transformative for incisionless surgery. This is a great example of how AI and robotics can have an incredible impact on all aspects of life.”
– Eliot Horowitz, Founder and CEO, Viam
This funding will not only allow us to scale our ambitious goal and technology, but continue to bring on world class talent. Our technology is built with the input of premier physicians, respected scientists and world class engineers. The result is a treatment that’s more effective and precise for patients, and a solution that is less bulky and more intuitive for operators to use. Our solution works with the body’s natural abilities to heal by creating vapor filled cavities one at a time, that allow for clear and connected treatment regions, with more opportunities to break down tougher tissues.
"At K50, we invest in consequential companies that propel the world forward. When it comes to health, we believe everyone, everywhere should have access to the care they need to live healthier, longer lives. Petal’s approach to incisionless surgery aligns powerfully with that vision. By reimagining surgical care from the ground up, Petal is making treatment safer, more accessible, and more equitable for patients across the globe."
– Ryan Bloomer, Founder and Managing Partner of K50 Ventures.
The Petal team is composed of leaders and pioneers of their respective fields who have come together to collaborate on a solution that is bigger than the sum of our parts. We’ve assembled a team with the collective belief that a better, and human, approach to surgery is possible.
We’re excited to emerge out of stealth and begin to share more about the innovation and human-centric approach we’re bringing to the world of healthcare. We can clearly see a world where incisionless surgery has become the norm and standard, in all communities - modern and developing, being an accessible yet hi-tech option to patients and eliminating risks and complications that are associated with surgery.
We invite you to stay close, as there will be more from us in the coming months. Please follow Petal on LinkedIn, Twitter/X, and Instagram.
About Petal:
Petal Surgical is pioneering a new field of incisionless surgery via a distinct form of histotripsy using robotics and AI. The company has raised $17.7 million to date, including a Series A financing round that was co-led by K50 Ventures and TSVC, supported by ShangBay Capital, and Dr. Frederic H. Moll, a pioneer in surgical robotics.
The company was founded by Prash Chopra, a seasoned image guided surgery engineer, along with Dr. Bowen Jiang (a neurosurgeon), Dr. Nicholas Theodore (a pioneer of robotic assisted spine surgery), and Rony Abovitz (founder of MAKO Surgical and MagicLeap).
